RecruitingColonic PolypSedation Complication
A Comparison of Remimazolam Besylate and Propofol Sedation in Patients Undergoing Colonoscopic Polypectomy
Eligible age
18–60 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this prospective, randomized, controlled study is to compare remimazolam besilat/sufentanyl and propofol/sufentanyl in patients during colonoscopic polypectomies procedures. Patients undergoing colonoscopic polypectomies in procedural sedation using remimazolam besylate/sufentanyl are circulatory and respiratory as or more stable when compared with propofol/sufentanyl sedation.
Sponsor: Clinical Hospital Centre Zagreb
You may qualify if…
- ✓ Patients both male and female
- ✓ ages 18 to 60 years,
- ✓ with one or more colonic polyps confirmed by colonoscopy and scheduled for a colonoscopy and polypectomy
- ✓ The duration of the colonoscopy ranges from 30 to 50 minutes.
- ✓ ASA status (American Society of Anaesthesiologists physical status) I-III.
- ✓ BMI (Body mass index) 18.5-29.9 kg/m2.
- ✓ Only patients who signed an informed consent waiver and consented to participate in the research study.
You may not qualify if…
- ✕ Patients aged \>60 years
- ✕ ASA status IV-V,
- ✕ BMI \>29.9 kg/m2,
- ✕ a high risk of vomiting, regurgitation and/or aspiration of gastric contents.
- ✕ Patients with:
- ✕ uncontrolled hypertension (systolic pressure \>160 mmHg),
- ✕ heart disease (cardiomyopathy, cardiac-rhythm disorder, left ventricular ejection fraction \<45%, stenosis or heart valve insufficiency and coronary heart disease)
- ✕ lung disease (pneumonia, chronic obstructive pulmonary disease, asthma and pulmonary tumors),
Source: ClinicalTrials.gov · NCT07456111 · last updated 2026-03-06